Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Biomedical Journal of Indonesia
Nathasya Ferdyastari
Department of Physiotherapy, Faculty of Health Science, Universitas Medika Suherman, Bekasi, Indonesia
Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Serum Creatine Kinase-MB Levels in Elderly Patients After Hemorrhagic and Ischemic Stroke Without a History of Heart Disease Mariel Daba; Nathasya Ferdyastari
Biomedical Journal of Indonesia Vol. 12 No. 1 (2026): Vol 12, No 1, 2026
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bji.v12i1.287

Abstract

Introduction. Elevations in cardiac biomarkers such as creatine kinase-MB (CK-MB) have been reported in stroke patients, even without clinical signs of heart disease. CK-MB, a cardiac-specific isoenzyme, indicates myocardial stress or injury. Exploring CK-MB dynamics in elderly post-stroke patients may provide insights into cardiovascular risk and prognosis. Methods. This comparative analytical cross-sectional study involved two groups of stroke patients admitted to Sentra Medika Hospital, Cikarang: hemorrhagic stroke (n=8) and ischemic stroke (n=8), totaling 16 participants. Inclusion criteria were age ≥60 years, stroke history within 3–6 months, and no cardiovascular disease based on medical records. Venous blood samples were collected to measure serum CK-MB levels using ELISA. Data were analyzed with an independent sample t-test. Results. A significant difference in mean CK-MB levels was observed (p=0.03). The hemorrhagic group had a mean CK-MB of 29 U/L, while the ischemic group had 26 U/L. Both values exceeded the reference level of <25 U/L, showing elevated CK-MB in both stroke types. Conclusion. Serum CK-MB levels were significantly elevated in elderly patients after hemorrhagic and ischemic stroke compared with normal values, suggesting CK-MB as a potential clinical marker in post-stroke patients.
Evaluation of Serum Brain-Derived Neurotrophic Factor Levels in Patients with Ischemic and Hemorrhagic Stroke Mariel Daba; Nathasya Ferdyastari
Biomedical Journal of Indonesia Vol. 12 No. 3 (2026): Vol 12, No 3, 2026, Issue in Progress
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bji.v12i3.338

Abstract

Introduction. Ischemic and hemorrhagic stroke arise from different vascular mechanisms and may therefore produce different neurobiological responses. Brain-Derived Neurotrophic Factor (BDNF) is involved in neuronal repair, synaptic remodeling, and recovery after brain injury. This study compared serum BDNF concentrations between ischemic and hemorrhagic stroke patients. Methods. A comparative cross-sectional study was conducted in 30 stroke patients recruited consecutively, with 15 participants in each diagnostic group. Eligibility included age 30-70 years, neuroimaging-confirmed stroke, onset between 6 and 48 days, MMSE score >18, and no other neurological comorbidity. Stroke severity was summarized using the National Institutes of Health Stroke Scale (NIHSS). Serum BDNF was quantified using an enzyme-linked immunosorbent assay (ELISA). Group differences were examined using an independent sample t-test after assessment of normality and homogeneity; ANCOVA was performed to adjust for age, onset, and NIHSS.  Results. Serum BDNF was higher in hemorrhagic stroke than in ischemic stroke (1.549 ± 0.016 vs. 1.457 ± 0.024 ng/mL, mean ± SEM; p = 0.004). The mean difference was 0.092 ng/mL, with a large standardized effect (Cohen’s d = 1.15). After adjustment for age, onset, and NIHSS, stroke type remained significantly associated with serum BDNF (β = 0.093; 95% CI: 0.030-0.155; p = 0.005) Conclusion. Serum BDNF differed between stroke subtypes, with higher levels in hemorrhagic stroke. These findings support the potential relevance of BDNF as a complementary biological marker in stroke research, although larger longitudinal studies are required before clinical application.
Co-Authors Mariel Daba Mariel Daba